Startups
Wave Life Sciences
Cambridge, Massachusetts, United States
Cambridge, Massachusetts biotechnology company developing investigational RNA medicines using its PRISM platform, which combines stereochemistry, human genetics and modalities including RNA editing, RNA interference, antisense silencing and splicing. Its neuroscience work includes Huntington’s disease, alongside programs in Duchenne muscular dystrophy, alpha-1 antitrypsin deficiency, obesity and liver disease. Wave was incorporated in Singapore in 2012, listed on Nasdaq as WVE in 2015, and completed redomiciliation to Delaware after trading on 7 August 2026, with its new common stock beginning Nasdaq trading on 10 August. Paul Bolno leads the company; its published leadership directory contains 11 executives and nine board members, with Bolno in both groups. GSK is an equity investor and research collaborator. As of 7 October 2026, the RNA medicines discussed here remain investigational: FDA feedback on the planned WVE-006 registrational pathway is distinct from approval or trial initiation. Equity fundraising is tracked separately from commercial research, licensing and milestone payments.
Founded 2012
Team
Adrian RawcliffeDirector |
Aik Na TanDirector |
 Chandra VargeeseChief Technology Officer |
 Chris FrancisChief Strategy Officer |
 Chris WrightChief Medical Officer |
 Christian HenryChair of the Board |
 Daryn LewisSenior Vice President, Head of Human Resources |
 Erik IngelssonChief Scientific Officer |
 Ginnie (Hsiu-Chiung) YangSenior Vice President, Translational Medicine |
Gregory VerdineFounder and Director |
Heidi WagnerDirector |
Ken TakanashiDirector |
 Kyle MoranChief Financial Officer |
 Linda RockettSenior Vice President, General Counsel |
 Mark CorriganDirector |
 Monika VnukChief Business Officer |
 Paul BolnoPresident and Chief Executive Officer · Director |
 Peter KolchinskyDirector |
 Sridhar VaddeboinaSenior Vice President, Chemistry, Manufacturing, and Controls |